I feel like people will only wake up to these once theyâve ten-bagged from the current level 
it came as a bit of a surprise that Compass is also a sub-billion market cap company 
2 Likes
I guess the crowd wonât wake up if no one wakes them. Thread created, heads up experts @JusaVaan @Junkbondking @Clark_kent @Johannes_Sippola
3 Likes
Okay, thanks, great! Thanks for the good introduction! Is it okay to write about other companies in the sector there (in which case, should the title be slightly fine-tuned)? Other companies like ATAI, GHRS, DFTX, HELP, are all interesting in their own way and, on a broad level, equally relevant players.
1 Like
I suppose that magic mushroom firms thread is a better home for those for the time being. Letâs definitely create more threads if lucrative investment opportunities are found. My preference is for Phase III companies or growth companies that have passed that stage, so early-stage firms donât appeal to me quite as much. DFTX is certainly interesting too!
3 Likes
Ok. Thereâs just nobody in that magic mushroom thread, so I havenât felt like posting there 
2 Likes
Itâll probably take off soon once WSB gets excited about these and the stock price multiplies 
3 Likes
By the way, ATAI has BPL-003 Phase 3 (2 trials) starting this quarter, and thereâs a rumor in the press that they might be seeking a deal for this molecule as early as this month (targeting a $2 billion deal value). Psychedelic Alpha interviewed an anonymous insider who clarified that the goal isnât to sell the entire molecule, but to partner with a BP (Big Pharma) that would also contribute to commercialization; royalty investors are also a possible option. Iâm hoping for a bidding war, because BPL-003 (5-MeO-DMT) looks like a solid IND! So soon you might have a Phase 3 company where the need for dilution has been eliminated through significant upfront and milestone payments! 
4 Likes
Nektar therapeutics
29% and 31% of patients in the 18 ”g/kg and 24 ”g/kg extension arms, respectively, achieved new SALT Score â€20 from week 36 to week 52 with continued twice-monthly treatment
Increasing proportions of patients achieved clinically meaningful hair growth thresholds across numerous SALT measurements with 94% of patients completing treatment extension
Results support advancement of rezpegaldesleukin into late-stage development in alopecia areata
5 Likes
Mielenkiintoinen, tuore artikkeli lÀÀkekehitykseen liittyvien lupaprosessien muutoksista!
1736 GMT â The FDAâs new single-trial approval policy could expand pharmaceutical development pipelines, J.P. Morgan analysts say in a research note. In February, the FDA Commissioner unveiled a new default position that just one âadequate and well-controlledâ study combined with confirmatory evidence will underpin marketing authorization of novel products. While the practice of conducting one, rather than two, pivotal trials is not a new phenomenon, the analysts say the formal implementation of the policy could drive pharmaceutical companies to reinvest savings from fewer Phase 3 trials into discovery and preclinical programs. Long term, this shift could gradually boost the total number of drugs reaching commercialization, the analysts say.(amira.mckee@wsj.com)
2 Likes
Another big in vivo CAR-T cell therapy deal. Eli Lilly is buying Kelonia for $7 billion, of which $3.25 billion is upfront and the rest in milestone payments. There is quite a lot of platform premium there, considering what stage the Kelonia pipeline is currently at.
https://www.fiercebiotech.com/biotech/lilly-picks-another-vivo-car-t-company-7b-deal-kelonia
There have been quite a few of these in vivo CAR-T deals lately. Quote from the link text:
"Lilly is a new entrant to the in vivo CAR-T field, having bought Orna Therapeutics for up to $2.4 billion in February. That acquisition followed in the footsteps of the likes of Gilead Sciences, which bought in vivo CAR-T company Interius BioTherapeutics for $350 million and inked a deal with Pregene worth as much as $1.6 billion.
Meanwhile, fellow U.S. pharma AbbVie bought autoimmune-focused in vivo CAR-T company Capstan Therapeutics for $2.1 billion last June, while Bristol Myers Squibb bagged Orbital Therapeutics for $1.5 billion in October and AstraZeneca took on EsoBiotec for $1 billion nearly a year ago."
4 Likes
Rezpeg has now shown promising placebo-controlled phase 2 efficacy in two autoimmune diseases with different underlying mechanisms. Never two without three?
In the investor call, a (grantedly selective) KOL was already suggesting that they would offer rezpeg as a first-line treatment to 100% of their patients. Currently, the only treatment in practice is JAK inhibitors, which come with black box warnings.
The US market for Alopecia is about 1 billion. But the availability of safer treatments would grow it significantly. Atopic dermatitis is a mega-market, but Dupixent has gained a foothold as a first-line biologic. In Alopecia, however, there is potential for a very high market share.
I donât use DCF because I canât be bothered (honestly, I donât know how). In any case, a DCF is only as good as its parameters. I prefer using a â1x peak salesâ estimate for fair value. It still shows upside for Nektar, though one must account for the phase 3 risk, which I personally consider to be quite low⊠Not investment advice.
4 Likes
ATAIâs results in the treatment of social anxiety disorder.
2 Likes
Yeah, the initial results for this were released in late February; todayâs publication includes additional analysis of efficacy evaluated using other metrics.
There was also a webcast about the results at the time. The share price dropped following the results, as investors were disappointed that the efficacy was mainly comparable to existing treatments, rather than some âmiracle cureâ that people have perhaps come to expect from psychedelic companies in their early phases.
This is R-MDMA, not a psychedelic in the classical sense. However, according to the company, the effect profile surprisingly resembles psychedelics, even more so than standard MDMA. To reduce cardiovascular side effects/impacts, this molecule provides less of a stimulant effect.
1 Like
Erasca released a massive data package yesterday, and the stock is down around -40% after hours because there was one grade 5 adverse event (the patient died). This was originally grade 3, but the patient refused treatment.
So Erasca is developing RAS inhibitors, which are a hot topic in oncology right now following Revolution Medicinesâ daraxonrasib data. Iâm tempted to say this is a massive overreaction, but I donât give investment advice!
2 Likes
Finally dumped Palisade Bio with about a 10% profit; apparently, a serious competitor put out strong data, which likely lowers Big Pharmaâs interest in the case.
Came across a few extremely hot biotechs. The ultimate multi-rocket-super-hyper-bagger being OS Therapeutics (OSTX)!
A roughly 100M market cap company developing a treatment for aggressive bone cancer. MASSIVE phase 2b results: 75% of patients alive at the 2-year mark (historically ~40%). A 200M PRV voucher potentially in the pipeline. Seriously, what a case!
4 Likes
It seems Palinâs rise was just beta returns. I havenât noticed anything new affecting the case so far. The next data probably wonât be out until H1/2027, so selling here might be smart since a breakout didnât happen.
Interesting, that OS Therapeutics, quite a wild mode of action indeed, and with âthe worldâs best biotech researcherâ Robert Langer as a strategic advisor 
. But the market is skeptical, the MoA is completely unproven, and osteosarcoma is a difficult disease. A very unfavorable TME, among other things.
1 Like
The market may have reacted to competitor data from the DDW conference (Mufemilast / Hemay)?
1 Like
Erascaâs Phase 1 results have now been published here. This is a massive data package that is worth digesting. However, the stock is at a -50% discount relative to its previous peak and the results are best-in-class (caveats: cross-trial comparison, Phase 1 data).
2 Likes
According to the news, competitor Revolution Medicine also just sued them for patent infringement; maybe thatâs weighing on things here?
Yes. Revolution now knows they are sitting on a gold mine. Since I lack the competence and time to evaluate whether the challenge has any merit, I assume it doesnât and that this is just normal territorial defense. Erasca, of course, already commented that the challenge is baselessâŠ
1 Like